Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
Xu Jiang,1 Sungyeun Bae,1 Deok Yong Yoon,2 Shin Jung Park,3 Jaeseong Oh,1 Joo-Youn Cho,1,4 Kyung-Sang Yu1,4 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea; 2Department of Pharmaceutics, Center for Pharmacome...
Main Authors: | Jiang X, Bae S, Yoon DY, Park SJ, Oh J, Cho JY, Yu KS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-07-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/comparison-of-the-pharmacokinetics-safety-and-tolerability-of-two-empa-peer-reviewed-fulltext-article-DDDT |
Similar Items
-
Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP®) Biosimilar, to Those of NESP® After a Single Subcutaneous or Intravenous Administration to Healthy Subjects
by: Jeon I, et al.
Published: (2021-04-01) -
Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
by: Choi C, et al.
Published: (2018-08-01) -
Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline
by: Si Nga Wong, et al.
Published: (2022-01-01) -
New Insights into the Use of Empagliflozin—A Comprehensive Review
by: Joanna Forycka, et al.
Published: (2022-12-01) -
Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
by: Yiya Wang, et al.
Published: (2022-08-01)